文献速递心律失常冠心病

房颤合并既往颅内出血患者的抗凝治疗:一项荟萃分析

Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis.
PubMed 文献 · Heart · 2023-10-12

结果显示,口服抗凝药(OAC)较未抗凝可降低缺血性卒中/系统性血栓栓塞(IS/SE)及全因死亡风险,不增加颅内出血复发,但增加大出血风险;非维生素K拮抗剂口服抗凝药(NOACs)较华法林颅内出血复发更少,疗效相当。

要点

  • OAC较未抗凝降低IS/SE(HR 0.54)与全因死亡(HR 0.38),不增加ICH复发。
  • OAC较大出血风险升高(HR 1.66),需权衡出血风险。
  • NOACs较华法林ICH复发更少(HR 0.64),疗效相当。

核心结论

  • 房颤合并既往颅内出血患者使用OAC可显著降低IS/SE和全因死亡,且不增加颅内出血复发,但可能增加大出血风险。
  • 与华法林相比,NOACs安全性更好且疗效相当。

研究设计与样本

  • 检索PubMed、Embase、Web of Science和Cochrane Library,检索时间自建库至2022年2月13日。

主要发现

  • OAC与未抗凝相比,颅内出血复发风险无显著增加(HR 0.85,95%CI 0.57–1.25,p=0.41)。
  • OAC与未抗凝相比,大出血风险显著增加(HR 1.66,95%CI 1.20–2.30,p<0.01)。
  • OAC与未抗凝相比,IS/SE风险降低(HR 0.54,95%CI 0.42–0.70,p<0.01),全因死亡风险降低(HR 0.38,95%CI 0.28–0.52,p<0.01)。
  • NOACs与华法林相比,颅内出血复发风险显著降低(HR 0.64,95%CI 0.49–0.85,p<0.01)。
  • NOACs与华法林相比,IS/SE和全因死亡风险相当。

临床怎么用

  • 对房颤合并既往颅内出血患者,可考虑启用OAC以降低缺血性卒中/系统性栓塞和死亡风险。
  • 优先选用NOACs而非华法林,因其颅内出血复发风险更低且疗效相当。
  • 启用OAC时需评估大出血风险并加强监测。

局限性

  • 纳入研究以真实世界研究为主,RCT样本量小(n=304)。
  • 需要更大规模的RCT验证上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit of resuming anticoagulation in atrial fibrillation (AF) patients with prior intracranial haemorrhage (ICH) and which anticoagulant to choose are controversial. SUMMARY OF REVIEW: PubMed, Embase, Web of Science and the Cochrane Library were searched from their inception until 13 February 2022. Thirteen eligible articles (17 600 participants) were collected, including 11 real-world studies (n=17 296) and 2 randomised controlled trials (RCTs) (n=304). Compared with no anticoagulants, oral anticoagulation (OAC) was not associated with an increased risk of ICH recurrence (HR 0.85 (95% CI 0.57 to 1.25), p=0.41), but with a significantly increased risk of major bleeding (HR 1.66 (95% CI 1.20 to 2.30), p<0.01). Meanwhile, OAC was associated with a reduced risk of ischaemic stroke/systemic thromboembolism (IS/SE) (HR 0.54 (95% CI 0.42 to 0.70), p<0.01) and all-cause death (HR 0.38 (95% CI 0.28 to 0.52), p<0.01) compared with no anticoagulants. Furthermore, compared with warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) were associated with a significant reduction of ICH recurrence (HR 0.64 (95% CI 0.49 to 0.85), p<0.01), while the risk of IS/SE and all-cause mortality were comparable between warfarin and NOACs. CONCLUSIONS: For patients with AF with prior ICH, OAC is associated with a significant reduction in IS/SE and all-cause mortality without increasing ICH recurrence, but may increase major bleeding risk. Compared with warfarin, NOACs had a better safety profile and comparable efficacy. Further larger RCTs are warranted to validate these findings.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Cai, Chen, Hu, et al. Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis. Heart. 2023. PMID: 37321829. doi:10.1136/heartjnl-2023-322492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。